QIAGEN Reports Third Quarter 2007 Results Increases Full Year 2007 Guidance

* 50% Revenue Growth * $0.17 Adjusted Diluted EPS * 43% Adjusted Operating Income Growth * Increasing Full Year 2007 Adjusted EPS Guidance by $0.03 to $0.61 - $0.62 Venlo, The Netherlands, November 5, 2007 - QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) today announced the results of operations for the third quarter and nine months ended September 30, 2007. QIAGEN's Third Quarter Q3 2007 Q3 2006 Growth Net sales (US$m) 176.6 117.9 50% Operating income, adj.[1] 43.7 30.6 43% Net income, adj. (US$)[2] 31.1 21.9 42% EPS, adj. (US$)[2] 0.17 0.14 21% [1] excluding acquisition, integration and restructuring related charges as well as amortization of acquired IP and equity-based compensation (SFAS 123R) as detailed in the table below [2] excluding acquisition, integration and restructuring related charges as well as amortization of acquired IP and equity-based compensation (SFAS 123R) as well as including a tax benefit of $0.02 in EPS in Q3 2007 as detailed in the table below QIAGEN's third quarter results include the results of operations of Digene Corp. and eGene, Inc. from the dates of acquisition, as well as one time charges related to these acquisitions. The Company reported that consolidated net sales for its third quarter 2007 increased 50% to $176.6 million from $117.9 million for the same period in 2006. In the three month period ended September 30, 2007, the Company reported an operating loss of $1.7 million as compared to operating income of $26.7 million reported in the same quarter of 2006, and reported a net loss for the quarter of $7.3 million, as compared to the net income of $19.4 million in the same quarter of 2006. Diluted earnings per share for the third quarter show a loss of $0.04 per share in 2007 from net income per share of $0.13 in 2006. On an adjusted basis, third quarter operating income increased 43% to $43.7 million in 2007 from $30.6 million in 2006, and third quarter 2007 adjusted net income increased 42% to $31.1 million from $21.9 million in 2006. Adjusted diluted earnings per share in the third quarter 2007 increased 21% to $0.17 per share, from $0.14 per share in the third quarter 2006. QIAGEN's Third Quarter 2007 at Constant Currencies 2007 2007 2006 Growth Rates As percentage Q3 Q3 Q3 of net sales, Constant Constant unless indicated Reported Currency Reported Reported Currency Consumables 89% 89% 89% 50% 45% Instruments 9% 9% 10% 44% 39% Others 2% 2% 1% 99% 90% Total revenues 100% 100% 100% 50% 45% Gross margin 66% 66% 68% 45% 42% Gross margin, adj.[1] 71% 72% 69% 54% 51% Operating income margin -1% -1% 23% -106% -106% Operating income margin, adj.[1] 25% 25% 26% 43% 43% Net income margin -4% -4% 16% -138% -138% Net income margin, adj.[2] 18% 18% 19% 42% 42% EPS in US$ per share -0.04 -0.04 0.13 EPS in US$ per share, adj.[2] 0.17 0.17 0.14 21% 21% [1] excluding acquisition, integration and restructuring related charges as well as amortization of acquired IP and equity-based compensation (SFAS 123R) as detailed in the table below [2] excluding acquisition, integration and restructuring related charges as well as amortization of acquired IP and equity-based compensation (SFAS 123R) and including a tax benefit of $0.02 in EPS in Q3 2007 as detailed in the table below For the nine-month period ended September 30, 2007, reported net sales increased 29% to $439.6 million compared to $339.9 million in the comparable period of 2006. Operating income as reported for the first nine months of 2007 decreased 21% to $58.1 million from $73.7 million for the same period in 2006, net income decreased 31% to $35.1 million from $51.1 million in 2006, and diluted earnings per share decreased 36% to $0.21 from $0.33 in 2006. On an adjusted basis, operating income for the nine-month period ended September 30, 2007 increased 29% to $112.5 million in 2007 from $87.5 million in 2006, and adjusted net income increased 30% to $79.4 million from $60.9 million. Adjusted diluted earnings per share in the nine months ended September 30, 2007 increased 20% to $0.48 per share from $0.40 per share in the same period of 2006. QIAGEN has regularly reported adjusted results to give an additional insight into its financial performance. Adjusted results should be considered in addition to the reported results prepared in accordance with generally accepted accounting principles, but should not be considered a substitute. The Company believes certain items should be excluded from adjusted results when they are either outside of our ongoing core operations or vary significantly from period to period, which affects the comparability of results with the Company's competitors and its own prior periods. Costs and charges excluded from adjusted results include acquisition, integration, restructuring and related costs, acquisition-related amortization, and compensation cost due to equity based compensation in accordance with Statement of Financial Accounting Standards No. 123 (SFAS 123R). QIAGEN's Adjustments to Gross Profit, Operating Income, Net Income and EPS In US$ millions unless indicated Q3 2007 Q3 2006 9 M 2007 9 M 2006 Gross profit 116.2 294.8 reported 80.1 232.1 Acquisition related 1.4 1.4 1.8 charges - Amortization of 8.4 12.2 4.3 acquired IP 1.7 Gross profit, 126.0 81.8 308.4 238.2 adjusted Operating (loss) (1.7) 58.1 income, reported 26.7 73.7 Acquisition and 5.9 7.9 6.7 integration related charges (incl. COS) 1.5 Purchased in-process 25.9 25.9 0.3 research & development - Relocation and - 0.5 0.8 restructuring charges - Amortization of 11.4 16.6 acquired IP (incl. COS) 2.4 5.8 SFAS 123R impact 2.2 - 3.5 0.2 Operating income, 43.7 30.6 112.5 87.5 adjusted Net (loss) income, (7.3) 35.1 reported 19.4 51.1 Acquisition and 3.8 5.1 integration related charges 0.9 5.1 Purchased in-process 25.9 25.9 research & development - 0.3 Relocation and - 0.4 0.6 restructuring charges - Amortization of 7.3 10.7 acquired IP 1.6 3.7 SFAS 123R impact 1.4 - 2.2 0.1 Net income, adjusted 31.1 21.9 79.4 60.9 Weighted average 177,919,000 number of basic common shares[1] Weighted average 185,481,000 153,755,000 166,193,000 153,106,000 number of diluted common shares EPS, reported in -0.04 0.21 US$[1] 0.13 0.33 EPS, adjusted in US$ 0.17 0.14 0.48 0.40 [1] Dilutive shares are not considered in the Q3 2007 reported dilutive loss per share as those shares would be antidilutive. "QIAGEN experienced a strong third quarter 2007. We saw revenue and earnings growth which were in line and above our expectations, respectively. Our pipeline of opportunities and products is one of the strongest ever." said Peer Schatz, QIAGEN's Chief Executive Officer. "Sales of our sample and assay technologies to customers in the Molecular Diagnostics field developed better than expected with a revenue contribution of approx. 42% to the overall business during the third quarter. We are progressing very well with our integration of Digene and can reaffirm our time plans and target cost synergies of between $35 and $45 million in 2008. With approximately 5% of all integration projects already completed and approximately 25% of the defined milestones already achieved." "Sales of QIAGEN sample and assay technologies to customers in molecular diagnostics associated with Women's Health/HPV showed strong growth. The importance of our franchise was underscored in the last few days and weeks by several studies which were performed using QIAGEN HPV testing solutions. In a landmark publication, the first randomized, controlled study of HPV testing as a primary, stand-alone screen for cervical cancer was performed in North America. This study involved more than 10,000 Canadian women age 30-69 and the study's authors concluded that HPV testing with QIAGEN's HPV test is almost 71% more accurate than traditional cytology (the "Pap smear") in identifying women with advanced cervical disease. These findings together with comparable results published in ten different trials in nine European countries with a total of approximately 190,000 patients provide further impetus to countries that have not yet implemented HPV screening programs to move towards the use of HPV testing as the primary screen - as opposed to its use as an adjunct assay in combination with the Pap Smear as it is currently implemented in the U.S." Taking into consideration the Company's strong performance during the third quarter, QIAGEN increased its guidance for adjusted diluted EPS (based on an estimated weighted average number of fully diluted shares outstanding of approximately 180 million) for the full year 2007 by $0.03 from the previously announced $0.55-$0.59 to $0.61-$0.62. QIAGEN also reiterated its revenue guidance for the full year 2007 of $614 - $635 million (based on constant exchange rates as of January 31, 2007) previously announced on August 6, 2007. "We are very pleased with the financial performance for the third quarter of 2007. Reported revenues were in line and adjusted earnings per share came in very strong and exceeded the Company's expectations," said Roland Sackers, QIAGEN's Chief Financial Officer. "We reported revenue growth for the third quarter of 50%, fueled by a strong organic growth of 10% and a positive contribution of 35% from acquisitions. In addition, our consumable portfolio exhibited 50% growth (45% growth at constant currencies). QIAGEN's instrumentation business showed a very strong growth rate of 39% at constant exchange rates. North American net sales for the third quarter represented approximately 52% of our overall business and grew at 70% at constant exchange rates while European sales, which represent approximately 37% of our revenues, exhibited a growth rate of approximately 23% at constant exchange rates. Net sales in Asia which represented approximately 9% of our revenues showed a growth rate of 29% at constant exchange rates driven by strong demand, primarily in China as well as from Singapore and Korea." Detailed information on the Company's business and financial performance will be presented in the Company's conference call on November 6, 2007 at 9:30am ET. The corresponding presentation slides will be available for download on the Company's website at www.qiagen.com/goto/071106 . A webcast of the conference call will be available on the same website at www.qiagen.com/goto/071106 . QIAGEN - Sample and Assay Technologies Highlights: * QIAGEN's manufacturing site in Shenzhen, which manufactures and markets diagnostic reagents for the in-vitro diagnostic (IVD) market in China submitted the application of "Medical Device Manufacturing Enterprise License" and has been approved by the Medical Device Registration Bureau. This additional, important and rare license follows the recently changed policy ("Administrative Rules on the Registration of In-Vitro-Diagnostic Reagents (On Trial)", enforced on 1st June 2007) which has changed the supervision of IVD reagents from the Drug Registration Bureau to the Medical Device Registration Bureau. * QIAGEN introduced its new call center for customers in all Asia Pacific markets as part of QIAGEN's globally coordinated Service Solutions Centers to support customers around the world 24 hours a day, 7 days a week. This call center includes a state of the art Application Laboratory as well as a Training Center and will support customers from all countries within Asia Pacific incorporating Service Solutions functions such as Technical Service, Customer Care, Training and Field Service for the Asia Pacific region. * The FDA has granted QIAGEN's manufacturing site in Hombrechtikon, Switzerland, which designs and manufactures the instruments for QIAGEN's automation business full cGMP compliance for instruments in clinical use. About QIAGEN: QIAGEN N.V., a Netherlands holding company is the leading provider of innovative sample and assay technologies and products. QIAGEN's products are considered standards in areas such pre-analytical sample preparation and assay solutions in research for life sciences, applied testing and molecular diagnostics. QIAGEN has developed a comprehensive portfolio of more than 500 proprietary, consumable products and automated solutions The company's products are sold to academic research markets, to leading pharmaceutical and biotechnology companies, to applied testing customers (such as in forensics, veterinary, biodefense and industrial applications) as well as to molecular diagnostics laboratories. QIAGEN employs more than 2,600 people worldwide. QIAGEN products are sold through a dedicated sales force and a global network of distributors in more than 40 countries. Further information about QIAGEN can be found at www.qiagen.com . Certain of the statements contained in this news release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, markets, strategy or operating results are forward-looking, such statements are based on current expectations that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations and risks of dependency on logistics), variability of operating results, the commercial development of the applied testing markets, clinical research markets and proteomics markets, women's health/HPV testing markets, nucleic acid-based molecular diagnostics market, and genetic vaccination and gene therapy markets, changing relationships with customers, suppliers and strategic partners, competition, rapid or unexpected changes in technologies, fluctuations in demand for QIAGEN's, products (including fluctuations due to the level and timing of customers' funding, budgets, and other factors), our ability to obtain regulatory approval of our infectious disease panels, difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products, the ability of QIAGEN to identify and develop new products and to differentiate its products from competitors' products, market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses. For further information, refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission (SEC). ### QIAGEN N.V. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) Three months ended September 30, 2007 2006 Net sales $176,632,000 $117,939,000 Cost of sales 50,695,000 36,167,000 Cost of sales - acquisition related 1,343,000 - Cost of sales - acquisition related intangible amortization 8,406,000 1,708,000 Gross profit 116,188,000 80,064,000 Operating Expenses: Research and development 17,870,000 10,125,000 Sales and marketing 45,162,000 28,707,000 General and administrative 21,470,000 12,389,000 Purchased in-process research and development 25,900,000 - Acquisition, integration and related costs 4,546,000 1,449,000 Acquisition related intangible amortization 2,951,000 651,000 Total operating expenses 117,899,000 53,321,000 (Loss) income from operations (1,711,000) 26,743,000 Other Income (Expense): Interest income 5,414,000 5,817,000 (Interest expense) (10,742,000) (4,546,000) Other income, net 1,084,000 262,000 Total other (expense) income (4,244,000) 1,533,000 (Loss) income before provision for income taxes and minority interest (5,955,000) 28,276,000 Provision for income taxes 1,380,000 8,918,000 Minority interest income (7,000) - Net (loss) income $(7,328,000) $19,358,000 Weighted average number of diluted common shares 185,481,000 153,755,000 Diluted net (loss) income per common share[1] $(0.04) $0.13 Diluted net income per common share excluding acquisition, integration and restructuring related charges as well as amortization of acquired IP and equity-based compensation (SFAS 123R) $0.17 $0.14 [1] Dilutive shares are not considered in the Q3 2007 reported dilutive loss per share as those shares would be antidilutive. Basic shares for Q3 2007 were 177,919,000. QIAGEN N.V. CONDENSED CONSOLIDATED STATEMENTS OF INCOME (unaudited) Nine months ended September 30, 2007 2006 Net sales $439,550,000 $339,887,000 Cost of sales 131,201,000 101,683,000 Cost of sales - acquisition related 1,343,000 1,745,000 Cost of sales - acquisition related intangible amortization 12,256,000 4,346,000 Gross profit 294,750,000 232,113,000 Operating Expenses: Research and development 42,091,000 30,548,000 Sales and marketing 108,460,000 83,888,000 General and administrative 48,760,000 36,499,000 Purchased in-process research and development 25,900,000 300,000 Acquisition, integration and related costs 6,582,000 4,979,000 Acquisition related intangible amortization 4,357,000 1,411,000 Relocation and restructuring costs 478,000 785,000 Total operating expenses 236,628,000 158,410,000 Income from operations 58,122,000 73,703,000 Other Income (Expense): Interest income 15,840,000 10,800,000 (Interest expense) (20,356,000) (7,938,000) Other income, net 1,965,000 1,679,000 Total other (loss) income (2,551,000) 4,541,000 Income before provision for income taxes and minority interest 55,571,000 78,244,000 Provision for income taxes 20,456,000 27,152,000 Minority interest income (7,000) - Net income $35,122,000 $51,092,000 Weighted average number of diluted common shares 166,193,000 153,106,000 Diluted net income per common share $0.21 $0.33 Diluted net income per common share excluding acquisition, integration and restructuring related charges as well as amortization of acquired IP and equity-based compensation (SFAS 123R) $0.48 $0.40 QIAGEN N.V. CONDENSED CONSOLIDATED BALANCE SHEETS September 30, December 31, 2007 2006 Assets (unaudited) Current Assets: Cash and cash equivalents $308,685,000 $430,357,000 Marketable securities - 52,782,000 Notes receivable 4,174,000 4,247,000 Accounts receivable, net 128,893,000 80,429,000 Income taxes receivable 7,747,000 2,901,000 Inventories 86,947,000 64,085,000 Deferred income taxes 48,211,000 18,627,000 Prepaid expenses and other 36,741,000 29,763,000 Total current assets 621,398,000 683,191,000 Long-Term Assets: Property, plant and equipment, net 276,709,000 221,277,000 Goodwill 1,113,497,000 160,141,000 Intangible assets, net 648,860,000 118,492,000 Deferred income taxes 7,534,000 2,409,000 Other assets 27,789,000 26,502,000 Total long-term assets 2,074,389,000 528,821,000 Total assets $2,695,787,000 $1,212,012,000 Liabilities and Shareholders' Equity Current Liabilities: Line of credit $6,000 $- Current portion of long-term debt - 6,599,000 Current portion of capital lease obligations 2,678,000 823,000 Accounts payable 35,409,000 23,806,000 Accrued and other liabilities 132,816,000 66,197,000 Income taxes payable 12,817,000 13,746,000 Deferred income taxes 3,741,000 5,360,000 Total current liabilities 187,467,000 116,531,000 Long-Term Liabilities: Long-term debt, net of current portion 949,999,000 489,592,000 Capital lease obligations, net of current portion 33,417,000 12,009,000 Deferred income taxes 183,464,000 21,705,000 Other 12,974,000 6,010,000 Total long-term liabilities 1,179,854,000 529,316,000 Minority interest in consolidated subsidiaries 497,000 - Shareholders' Equity: Common shares, EUR .01 par value: Authorized--260,000,000 shares Issued and outstanding--192,692,524 shares in 2007 and 150,167,540 shares in 2006 2,138,000 1,535,000 Additional paid-in-capital 886,198,000 178,656,000 Retained earnings 373,779,000 344,739,000 Accumulated other comprehensive income 65,854,000 41,235,000 Total shareholders' equity 1,327,969,000 566,165,000 Total liabilities and shareholders' equity $2,695,787,000 $1,212,012,000 --- End of Message --- Qiagen N.V. Spoorstraat 50 KJ Venlo Netherlands WKN: 901626; ISIN: NL0000240000; Index: HDAX, MIDCAP, Prime All Share, TECH All Share, TecDAX; Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in Börse Berlin, Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg, Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in Bayerische Börse München, Freiverkehr in Börse Stuttgart;